Table 1.

Prevalence of APOL1 risk alleles among HIV renal histologies.

Disease	Country	N cases	APOL1 2 RA prevalence in reference population (HIV status)	APOL1 2 RA prevalence in disease	Odds ratio (CI) for kidney disease, when 2 APOL1 risk alleles are present	Reference
HIVAN	USA	54	8% (HIV+)	72%	29 (14, 68)	(Kopp et al. 2011)
	USA	60	ND	62%	ND	(Atta et al. 2012)
	South Africa	38	3.7% (HIV+)	79%	89 (18, 912)	(Kasembeli et al. 2015)
HIVICK	USA	31	ND	3%	ND	(Fine et al. 2012)
	South Africa	49	3.7% (HIV+)	9%	2.6 (NS)	(Kasembeli et al. 2015)
HIV+ FSGS	USA	35	8% (HIV+)	63%	20 (8, 45)	(Fine et al. 2012)
	USA	203-X	ND	X	3 (1.5, 6)	(Atta et al. 2016)
	South Africa	22	3.7% (HIV+)	8%	2.1 (NS)	(Kasembeli et al. 2015)
HIV-negative FSGS	USA	217	13% (HIV-)	72%	17 (11,26)	(Kopp et al. 2011)

Shown are the results of studies that have examined the prevalence of APOL1 high-risk individuals (those carrying two APOL1 risk alleles) among HIV+ individuals with particular renal histologies. The rates of APOL1 two risk allele carriage for the control population are 13% in the general US African American population in the Kopp et al study, 4% in the general South African population in the Kasembeli et al study, and 8% among HIV+ African Americans lacking kidney disease in Kopp et al study. Odds ratio was calculated from data in Fine et al, using data from the HIV+ African American population, lacking kidney disease, taken from the Kopp et al study.

HIVAN, HIV nephropathy. HIVICK, HIV-associated immune complex kidney disease. ND, not determined. NS, not significant.